EP Patent

EP2773345A1 — Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors

Assigned to Synta Phamaceuticals Corp · Expires 2014-09-10 · 12y expired

What this patent protects

A pharmaceutical combination comprising a topoisomerase I inhibitor, and an Hsp90 inhibitor according to the following formulae (I) (la) a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided i…

USPTO Abstract

A pharmaceutical combination comprising a topoisomerase I inhibitor, and an Hsp90 inhibitor according to the following formulae (I) (la) a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided is a method for treating a proliferative disorder in a subject in need thereof, using the pharmaceutical combination described herein.

Drugs covered by this patent

Patent Metadata

Patent number
EP2773345A1
Jurisdiction
EP
Classification
—
Expires
2014-09-10
Drug substance claim
No
Drug product claim
No
Assignee
Synta Phamaceuticals Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.